Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01741896
Other study ID # Feeley01
Secondary ID
Status Completed
Phase N/A
First received December 4, 2012
Last updated September 12, 2013
Start date November 2012
Est. completion date March 2013

Study information

Verified date September 2013
Source Mid Western Regional Hospital, Ireland
Contact n/a
Is FDA regulated No
Health authority Republic of Ireland: Mid Western Regional Hospital
Study type Interventional

Clinical Trial Summary

Computated tomography (CT) is an invaluable medical resource for both physicians and surgeons. Contrast media are an aid to improve the diagnostic yield of CT. While an incredibly powerful means of imaging the human body, there are possible complications to the use of contrast including a hypersensitive response and contract induced nephropathy (CIN). The latter will typically occur 48-72 hours after administration.

One recent meta - analysis of serum creatinine levels following contrast enhanced CT found 6.4% of those undergoing this investigation developed CIN. Although typically transient, 1 % had a persisting reduced renal function, with a small minority needing renal replacement therapy (RRT). The development of CIN was influenced by co morbidities and by the amount of contrast given.

The mechanism of injury to the kidney is not definitively established, but is thought most likely due to hypoxia resulting from reduced blood flow, thereby giving rise to oxygen free radicals causing direct damage to the kidney and also direct tubular damage.

Remote conditioning ischaemia has been hypothesized to be nephroprotective, whereby induced transient ischaemia at another site could buffer the impact of the contrast medium's effects. This was first demonstrated during cardiac angiograms, with those patients whom received multiple balloon inflations in the coronary arteries were found to have a lower incidence of CIN than those with fewer balloon inflations. Thus it could be hypothesised that any ischaemia temporarily induced could be nephroprotective. This can be at a point of extremity, rather than involving central organs, such as the arm, with ischaemia induced by the use of a blood pressure cuff, inflated to above systolic blood pressure levels.

No studies have been found in the literature attempting to demonstrate this effect in relation to contrast CT studies. Consequently, a randomised control clinical trial of patients to assess the effectiveness of remote ischaemic preconditioning is proposed.

Study Hypothesis: That performing remote ischaemic preconditioning on those undergoing CTs involving IV contrast is nephroprotective.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 17 Years and older
Eligibility Inclusion Criteria:

- Hospital inpatients undergoing contrast enhanced abdomino-pelvic CT scanning.

Exclusion Criteria:

- Those with an allergy/hypersensitivity to the contrast solution

- Those with a Cr of above 150µmol/dL on admission, as is a contraindication to IV contrast.

- Patients who are not getting IV contrast

- Any patients with a history of renal transplantation

- Any patients with a history of previous acute kidney injury necessitating management by a nephrologist

- Patients taking either a sulphonlurea or nicorandil.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Procedure:
Remote ischaemic preconditioning
The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.

Locations

Country Name City State
Ireland Mid Western Regional Hospital Limerick

Sponsors (1)

Lead Sponsor Collaborator
Mid Western Regional Hospital, Ireland

Country where clinical trial is conducted

Ireland, 

References & Publications (2)

Walsh SR, Tang TY, Sadat U, Gaunt ME. Remote ischemic preconditioning in major vascular surgery. J Vasc Surg. 2009 Jan;49(1):240-3. doi: 10.1016/j.jvs.2008.07.051. Epub 2008 Oct 1. Review. — View Citation

Whittaker P, Przyklenk K. Remote-conditioning ischemia provides a potential approach to mitigate contrast medium-induced reduction in kidney function: a retrospective observational cohort study. Cardiology. 2011;119(3):145-50. doi: 10.1159/000330930. Epub 2011 Sep 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in eGFR in those undergoing CT with IV contrast The study aims to define the effectiveness in the nephroprotective properties of remote ischaemic preconditioning. The outcome measures are the eGFR at 24 and 48 hours post infusion of IV contrast compared to preinfusion levels, in groups randomised into either undergoing RIPC or a control group. 48 hours No
See also
  Status Clinical Trial Phase
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00634491 - Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy Phase 2
Terminated NCT00476619 - Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial Phase 4
Recruiting NCT03121053 - Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Phase 4
Completed NCT02650336 - Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial N/A
Terminated NCT00575419 - Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure Phase 1
Not yet recruiting NCT00392405 - Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate Phase 2
Completed NCT00292487 - Patients With Renal Impairment Undergoing CT Phase 4
Recruiting NCT04982419 - Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial Phase 2/Phase 3
Completed NCT00770614 - Hydration and Contrast-Induced Nephropathy in Primary Angioplasty Phase 4
Completed NCT01999517 - Contrast Nephropathy and Nitrates Phase 4
Recruiting NCT00702728 - Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention Phase 3
Completed NCT00639912 - Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction. Phase 4
Completed NCT00531765 - Sodium Bicarbonate in Preventing Contrast Induced Nephropathy N/A
Terminated NCT00494637 - The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy N/A
Completed NCT02516072 - Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy N/A
Active, not recruiting NCT01402232 - REduction of rIsk for Contrast Induced Nephropathy
Recruiting NCT02113540 - Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography Phase 3
Active, not recruiting NCT01456013 - Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients Phase 3
Recruiting NCT01399203 - Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention N/A